EMA Authorised: Apidra (insulin glulisine) — sanofi-aventis Deutschland GmbH

View source ↗

Summary

EMA authorised Apidra, insulin glulisine, for diabetes mellitus with sanofi-aventis Deutschland GmbH as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Apidra (insulin glulisine)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: sanofi-aventis Deutschland GmbH. Decision date: 05/03/2026